Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BRAIN Biotech AG's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was €-0.16.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.51.
During the past 3 years, the average earnings per share (NRI) Growth Rate was -12.40% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was -2.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for BRAIN Biotech AG's EPS without NRI or its related term are showing as below:
HAM:BNN'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -12.4 Med: 3.8 Max: 15.2
Current: -12.4
During the past 11 years, BRAIN Biotech AG's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 15.20% per year. The lowest was -12.40% per year. And the median was 3.80% per year.
HAM:BNN's 3-Year EPS without NRI Growth Rate is ranked worse than 65% of 1257
companies
in the Chemicals industry
Industry Median: -1.7
vs HAM:BNN: -12.40
BRAIN Biotech AG's EPS (Diluted) for the
three
months ended in Mar. 2026 was €-0.16.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.51.
BRAIN Biotech AG's EPS (Basic) for the
three
months ended in Mar. 2026 was €-0.16.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.51.
BRAIN Biotech AG (HAM:BNN) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
BRAIN Biotech AG EPS without NRI Related Terms
BRAIN Biotech AG EPS without NRI Historical Data
* Premium members only.
The historical data trend for BRAIN Biotech AG's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:BNN vs LIN, SHW, ECL: EPS without NRI Comparison
For the Specialty Chemicals subindustry, BRAIN Biotech AG's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BRAIN Biotech AG PE Ratio without NRI vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where BRAIN Biotech AG's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.51
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BRAIN Biotech AG (HAM:BNN) has a EPS without NRI of €-0.51 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on BRAIN Biotech AG and its competitors. According to the industry distribution chart, BRAIN Biotech AG ranks #817 out of 1257 companies in the Chemicals industry, placing it in the top 65%.
Is BRAIN Biotech AG's EPS without NRI too high?
BRAIN Biotech AG's current EPS without NRI is €-0.51. Based on the distribution chart, BRAIN Biotech AG ranks #817 out of 1257 companies in the Chemicals industry, which is below the industry midpoint. Overall, BRAIN Biotech AG has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BRAIN Biotech AG's EPS without NRI compare to LIN and SHW?
According to the Chemicals industry distribution chart, BRAIN Biotech AG ranks #817 out of 1257 companies for EPS without NRI. This places BRAIN Biotech AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Chemicals company?
A good EPS without NRI depends on the Chemicals industry context. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on BRAIN Biotech AG and its competitors. BRAIN Biotech AG's current EPS without NRI is €-0.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRAIN Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, BRAIN Biotech AG (HAM:BNN) is currently considered Modestly Overvalued. The stock's GF Value™ is €2.49, compared to a current price of €2.78 — trading 11.6% above its estimated fair value. The current EPS without NRI is €-0.51. BRAIN Biotech AG's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For BRAIN Biotech AG (HAM:BNN), the current EPS without NRI is €-0.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BRAIN Biotech AG (HAM:BNN) Overvalued in 2026?
Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued.
The current stock price of €2.78 is trading 11.6% above its estimated GF Value™ of €2.49.
GuruFocus considers BRAIN Biotech AG to be Modestly Overvalued.
Key valuation signals for HAM:BNN:
EPS without NRI: €-0.51
GF Value™: €2.49 vs. price of €2.78 (11.6% above fair value)
No single metric tells the full story. See the HAM:BNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
69GF Score
Get the complete analysis for HAM:BNN
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:BNN has been successfully added to your 
